Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the Inflation Reduction Act (IRA). What does this mean for pharmaceutical manufacturers?
Join us for an engaging discussion with Max Hunt, Partner at Trinity Life Sciences, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage. The webinar will explore trends in drug spending, the impact of the IRA Part D redesign, learnings from the latest cycle of negotiations and implications for manufacturers.
Whether you’re launching a new therapy or managing an innovative drug, gain the insights you need to stay ahead in the dynamic payer and policy landscape in the U.S.
Key Webinar Topics
- Drug spending trends in 2024 and 2025 to date, including the impact of the IRA Part D redesign
- Learnings from the most recent cycle of manufacturer and Medicare Advantage/Part D negotiations for 2026
- Expectations for access to Medicare Advantage and Part D for innovative drugs and new launches in the next 2-3 years
- Implications for manufacturers of innovative drugs on the market and those that will launch in this period
Complete the form below to view the on-demand webinar
By clicking "I agree" above, you are agreeing that Trinity will use and protect your personal data in accordance with our Privacy Policy. You can opt out of future marketing communications at any time by clicking the unsubscribe link at the bottom of any marketing email you receive from Trinity.